title: Endothelin type A receptor antagonism restores myocardial perfusion response to adenosine in experimental hypercholesterolemia.
abstract: Experimental hypercholesterolemia is characterized by increased endothelin-1 (ET-1) activity and is associated with an attenuated myocardial perfusion response and an inappropriate increase in coronary microvascular permeability during episodes of increased myocardial demand. This study was designed to determine the effect of chronic selective ET type A (ET(A)) receptor antagonism on coronary vascular response to simulated cardiac stress in experimental hypercholesterolemia. Twenty-one pigs were randomized to three groups: normal diet (N), high-cholesterol diet (HC), and HC diet plus ABT-627, a selective ET(A) receptor antagonist, (HC+ABT-627). After 12 weeks, cardiac electron beam computed tomography (EBCT) was performed before and during intravenous infusion of adenosine, and myocardial perfusion (ml/min per g) and coronary microvascular permeability index (arbitrary units) were calculated. Basal myocardial perfusion was similar in all groups (N: 0.91+/-0.10; HC: 0.95+/-0.08; HC+ABT-627: 1.03+/-0.09; P=0.64). Adenosine infusion led to a significant increase in myocardial perfusion in the N (1.32+/-0.15; P<0.001) but not in the HC (0.95+/-0.07) group. However, in the HC+ABT-627 group, adenosine also significantly increased myocardial perfusion (1.33+/-0.12; P=0.001). Basal permeability index did not differ between the groups (N: 1.56+/-0.13; HC: 1.34+/-0.19; HC+ABT-627: 1.62+/-0.10; P=0.38). Adenosine infusion significantly increased permeability index in HC pigs (2.29+/-0.22; P<0.001) but not in N (1.71+/-0.21) and HC+ABT-627 (1.82+/-0.08) pigs. We conclude that chronic selective ET(A) receptor antagonism preserves myocardial perfusion response and coronary microvascular integrity during episodes of increased myocardial demand in experimental hypercholesterolemia, indicating an important role for the endogenous endothelin system in this disorder.
authors.affiliation: Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Piero O
authors.initials: PO
authors.lastname: Bonetti
authors.forename: Patricia J M
authors.initials: PJ
authors.lastname: Best
authors.forename: Martin
authors.initials: M
authors.lastname: Rodriguez-Porcel
authors.forename: David R
authors.initials: DR
authors.lastname: Holmes
authors.forename: Lilach O
authors.initials: LO
authors.lastname: Lerman
authors.forename: Amir
authors.initials: A
authors.lastname: Lerman
mesh_terms: D000241:Adenosine / Q000494:pharmacology*; D000818:Animals; D000077868:Atrasentan; D001835:Body Weight; D002199:Capillary Permeability; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D003326:Coronary Circulation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D065128:Endothelin Receptor Antagonists; D006439:Hemodynamics; D006937:Hypercholesterolemia / Q000473:pathology / Q000503:physiopathology*; D008055:Lipids / Q000097:blood; D008833:Microcirculation; D020033:Protein Isoforms / Q000037:antagonists & inhibitors; D011759:Pyrrolidines / Q000494:pharmacology; D013552:Swine
chemical_list: D002791:Cholesterol, Dietary; D065128:Endothelin Receptor Antagonists; D008055:Lipids; D020033:Protein Isoforms; D011759:Pyrrolidines; D000241:Adenosine; D000077868:Atrasentan